LifeStance Health Group, Inc. (LFST) - What Are Analysts Saying About This Stock?

Key Points

• Analysts remain broadly positive: LifeStance Health Group has a “Moderate Buy” consensus from 11 analysts, with an average 12-month price target of $13.12. Recent firms raised targets as high as $18.
• Business performance exceeded expectations: The company reported quarterly EPS of $0.06 versus the $0.03 consensus and revenue of $435.35 million, up 26.1% year over year.
• Shares have risen sharply, but insider selling is notable: LFST traded near its 12-month high at $13.64, while insiders sold approximately $146.4 million of stock over the past 90 days; institutional investors own 85.5% of shares.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.12.

Several brokerages have recently issued reports on LFST. Canaccord Genuity Group boosted their price objective on LifeStance Health Group from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, September 9th. BTIG Research raised their target price on LifeStance Health Group from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, August 19th. JPMorgan Chase & Co. raised their target price on LifeStance Health Group from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Wall Street Zen lowered LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 5th. Finally, Barclays boosted their price target on LifeStance Health Group from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday, September 10th.

LifeStance Health Group Trading Up 1.9%

NASDAQ:LFST opened at $13.64 on Friday. The firm has a market capitalization of $5.21 billion, a P/E ratio of 104.93 and a beta of 1.24. The business has a 50 day simple moving average of $12.47 and a 200 day simple moving average of $9.31. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. LifeStance Health Group has a 12-month low of $4.77 and a 12-month high of $13.65.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%. The company had revenue of $435.35 million for the quarter, compared to analysts' expectations of $414.58 million. During the same period last year, the business posted ($0.01) earnings per share. The firm's quarterly revenue was up 26.1% compared to the same quarter last year. Equities research analysts predict that LifeStance Health Group will post 0.16 EPS for the current year.

Insider Activity at LifeStance Health Group

In related news, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the transaction, the chief operating officer owned 281,289 shares in the company, valued at $3,051,985.65. This represents a 14.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CTO Vukasin Paunovich sold 42,067 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total transaction of $541,402.29. Following the sale, the chief technology officer owned 205,379 shares in the company, valued at $2,643,227.73. This trade represents a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,777,580 shares of company stock worth $146,433,781 over the last ninety days. 3.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Profund Advisors LLC raised its position in LifeStance Health Group by 7.1% in the third quarter. Profund Advisors LLC now owns 11,944 shares of the company's stock worth $144,000 after acquiring an additional 788 shares in the last quarter. ProShare Advisors LLC lifted its holdings in LifeStance Health Group by 24.2% in the 3rd quarter. ProShare Advisors LLC now owns 34,469 shares of the company's stock valued at $415,000 after acquiring an additional 6,727 shares during the last quarter. Vise Technologies Inc. boosted its position in shares of LifeStance Health Group by 38.8% during the 3rd quarter. Vise Technologies Inc. now owns 22,511 shares of the company's stock valued at $271,000 after purchasing an additional 6,294 shares in the last quarter. State of Wyoming boosted its position in shares of LifeStance Health Group by 10.4% during the 3rd quarter. State of Wyoming now owns 75,836 shares of the company's stock valued at $912,000 after purchasing an additional 7,158 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of LifeStance Health Group by 57.3% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 36,500 shares of the company's stock valued at $439,000 after purchasing an additional 13,300 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.